EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy

Stephen E Flaherty, LouJin Song, Bina Albuquerque, Anthony Rinaldi, Mary Piper, Dinesh Hirenallur Shanthappa, Xian Chen, John Stansfield, Shoh Asano, Evanthia Pashos, Trenton Thomas Ross, Srinath Jagarlapudi und 3 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.13715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Stephen E Flaherty und 14 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Mitochondrial Myopathies, Muscular Atrophy, Exercise Tolerance. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary mitochondrial myopathies (PMMs) are disorders caused by mutations in genes encoding mitochondrial proteins and proteins involved in mitochondrial function. PMMs are characterized by loss of muscle mass and strength as well as impaired exercise capacity. Growth/Differentiation Factor 15 (GDF15) was reported to be highly elevated in PMMs and cancer cachexia. Previous studies have shown that GDF15 neutralization is effective in improving skeletal muscle mass and function in cancer cachexia. It remains to be determined if the inhibition of GDF15 could be beneficial for PMMs. The purpose of the present study is to assess whether treatment with a GDF15 neutralizing antibody can alleviate muscle atrophy and physical performance impairment in a mouse model of PMM.

Methods

The effects of GDF15 neutralization on PMM were assessed using Polg D257A/D257A (POLG) mice. These mice express a proofreading‐deficient version of the mitochondrial DNA polymerase gamma, leading to an increased rate of mutations in mitochondrial DNA (mtDNA). These animals display increased circulating GDF15 levels, reduced muscle mass and function, exercise intolerance, and premature aging. Starting at 9 months of age, the mice were treated with an anti‐GDF15 antibody (mAB2) once per week for 12 weeks. Body weight, food intake, body composition, and muscle mass were assessed. Muscle function and exercise capacity were evaluated using in vivo concentric max force stimulation assays, forced treadmill running and voluntary home‐cage wheel running. Mechanistic investigations were performed via muscle histology, bulk transcriptomic analysis, RT‐qPCR and western blotting.

Results

Anti‐GDF15 antibody treatment ameliorated the metabolic phenotypes of the POLG animals, improving body weight (+13% ± 8%, p < 0.0001), lean mass (+13% ± 15%, p < 0.001) and muscle mass (+35% ± 24%, p < 0.001). Additionally, the treatment improved skeletal muscle max force production (+35% ± 43%, p < 0.001) and exercise performance, including treadmill (+40% ± 29%, p < 0.05) and voluntary wheel running (+320% ± 19%, p < 0.05). Mechanistically, the beneficial effects of GDF15 neutralization are linked to the reversal of the transcriptional dysregulation in genes involved in autophagy and proteasome signalling. The treatment also appears to dampen glucocorticoid signalling by suppressing circulating corticosterone levels in the POLG animals.

Conclusions

Our findings highlight the potential of GDF15 neutralization with a monoclonal antibody as a therapeutic avenue to enhance physical performance and mitigate adverse clinical outcomes in patients with PMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15Mitochondrial MyopathiesMuscular AtrophyExercise ToleranceAntibodies, NeutralizingAnimalsMiceDisease Models, AnimalMuscle, SkeletalMalePhysical Conditioning, Animal

Stichwörter der Autor:innen

GDF15antibodymicemitochondriamuscleprimary mitochondrial myopathy

Substanzen

Growth Differentiation Factor 15Antibodies, NeutralizingGdf15 protein, mouse

Autor:innen und Institutionen

  • Internal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA.
  • Obesity and Complications, Eli Lilly, Boston, Massachusetts, USA.
  • Diabetes, Obesity and MASH, Global Drug Discovery, Novo Nordisk, Lexington, Massachusetts, USA.
  • Program Mamager, Preclinical Sciences, Toxicology, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
  • Biostatistics, Early Clinical Development, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA.
  • Inflammation and Immunology Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, USA.

ORCID-Profile: Zhidan Wu

Zitieren

APA

Flaherty, S. E., Song, L., Albuquerque, B., Rinaldi, A., Piper, M., Shanthappa, D. H., Chen, X., Stansfield, J., Asano, S., Pashos, E., Ross, T. T., Jagarlapudi, S., Sheikh, A., Zhang, B., & Wu, Z. (2025). GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13715

Vancouver

Flaherty SE, Song L, Albuquerque B, Rinaldi A, Piper M, Shanthappa DH, et al. GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13715

BibTeX
@article{Flaherty2025,
  author = {Flaherty, Stephen E and Song, LouJin and Albuquerque, Bina and Rinaldi, Anthony and Piper, Mary and Shanthappa, Dinesh Hirenallur and Chen, Xian and Stansfield, John and Asano, Shoh and Pashos, Evanthia and Ross, Trenton Thomas and Jagarlapudi, Srinath and Sheikh, Abdul and Zhang, Bei and Wu, Zhidan},
  title = {GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13715}
}
Kostenlos starten →